GlassScriptPhysician profile
Reza Khoshini
NPI 1184772014
$5,051.48
in general payments reported to CMS, 2019-2025
29 companies · $2,227 in 2025
The $2,227 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $113 · 2021: $330 · 2022: $509 · 2023: $722 · 2024: $838 · 2025: $2,227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,337 · Consulting Fee: $1,450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,336.83 |
| Consulting Fee | $1,450.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Medical Systems Corporation | $1,450.00 | 2025 | Evis Exera III Duodenovideoscope |
| Abbvie INC. | $1,307.67 | 2019-2025 | |
| Janssen Biotech, INC. | $482.83 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $290.73 | 2019-2025 | Entyvio, Vpriv, Eohilia |
| Pfizer INC. | $249.07 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $143.07 | 2020-2024 | Trulance |
| Ferring Pharmaceuticals INC. | $123.13 | 2019-2023 | Rebyota |
| Genzyme Corporation | $120.91 | 2023-2025 | |
| Boston Scientific Corporation | $114.69 | 2025 | Axios |
| Intercept Pharmaceuticals, INC. | $102.27 | 2019-2023 | Ocaliva |
| Gilead Sciences, INC. | $69.72 | 2019-2023 | |
| Aimmune Therapeutics, INC. | $58.99 | 2024 | |
| Ardelyx, INC. | $57.58 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $56.79 | 2024 | Omvoh |
| Vivus LLC | $54.59 | 2024-2025 | Qsymia, Pancreaze |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $51.30 | 2019-2022 | |
| Medtronic, INC. | $37.30 | 2023 | Pillcam |
| Phathom Pharmaceuticals, INC. | $37.14 | 2024-2025 | Voquezna |
| Cook Medical LLC | $36.21 | 2025 | Hemospray |
| Orphalan INC | $31.70 | 2024 | Cuvrior |
| Evoke Pharma, INC. | $27.77 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $26.44 | 2023 | Dupixent |
| Olympus America INC. | $23.00 | 2024 | Single Use Electrosurgical Knife Kd-655 |
| Amag Pharmaceuticals, INC. | $22.96 | 2019 | |
| Daiichi Sankyo INC. | $22.25 | 2021 | |
| Madrigal Pharmaceuticals | $20.41 | 2025 | Rezdiffra |
| Shionogi INC | $16.98 | 2019 | |
| Nestle Healthcare Nutrition INC. | $13.92 | 2023 | |
| Micro-Tech Endoscopy USA, INC. | $2.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reza Khoshini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.